Saijo et al. (2017) reported the first tau RT-QuIC, which utilises K19CFh synthetic 3R tau fragment as substrate and was developed using Pick’s disease brain homogenates but attained 91%–100% sensitivity when applied to post-mortem Pick’s disease CSF and 94%–100% specificity when applied to ante-mortem control CSF. The gene discussed is MAPT; the disease is Pick disease.